Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Ltd, has been named EY World Entrepreneur Of The Year 2020. Mazumdar-Shaw was picked from among 46 award winners from 41 countries and territories vying for the world title, EY said in a press release.
Who has been named EY Entrepreneur?
EY Entrepreneur Of The Year 2020
Harsh C. Mariwala was named the EY Entrepreneur Of The Year 2020 during a virtual Awards ceremony.
Who has been named the EY Entrepreneur of 2020?
(BYJU’S) won the business transformation award. NSE -0.46 %, on Thursday won EY Entrepreneur of the year award. Mariwala, and will now represent India at the EY World Entrepreneur of the Year Award (WEOY) on 10 June 2021.
Who won EY Entrepreneur of the Year 2019?
Kiran Mazumdar Shaw, Chairperson and Managing Director, Biocon, was today named the EY Entrepreneur Of The Year 2019 and will now represent India at the EY World Entrepreneur Of The Year Award (WEOY) in Monte Carlo from 4–6 June 2020.
Who founded Biocon?
Siddhartha Lal, Managing Director and Chief Executive Officer, Eicher Motors, was named the EY Entrepreneur of the Year 2018 at the 20th edition of the EOY Awards in India.
How many EY offices are there?
With over 700 office locations in over 150 countries, we provide local knowledge with global experience.
What was the revenue of EY globally in 2020?
Combined revenue of EY worldwide from 2009 to 2021, by region (in billion U.S. dollars)
What awards have EY won?
- SAS 2020 Global Partner of the Year.
- SAS 2019 Partner of the Year Asia Pacific.
- SAS 2018 Excellence in Innovation Award.
Who is the chairman of Biocon?
Kiran Mazumdar-Shaw is the Chairperson and Managing Director of Biocon, Asia’s leading bio-pharmaceuticals enterprise. Named among TIME magazine’s 100 most influential people in the world, she is recognized as a global thought leader for Biotechnology.
Who is the head of Biocon?
Biocon Limited is India’s largest and fully-integrated, innovation-led biopharmaceutical company. Some of its key brands are INSUGEN (rh-insulin), BASALOG (Glargine), CANMAb (Trastuzumab), BIOMAb-EGFR (Nimotuzumab), KRABEVAA (Bevacizumab) and ALZUMAb (Itolizumab), a ‘first in class’ anti-CD6 monoclonal antibody.